JP2005532330A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005532330A5 JP2005532330A5 JP2004506803A JP2004506803A JP2005532330A5 JP 2005532330 A5 JP2005532330 A5 JP 2005532330A5 JP 2004506803 A JP2004506803 A JP 2004506803A JP 2004506803 A JP2004506803 A JP 2004506803A JP 2005532330 A5 JP2005532330 A5 JP 2005532330A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- inhibitor
- hypertension
- receptor antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003839 salts Chemical class 0.000 claims description 40
- 206010020772 Hypertension Diseases 0.000 claims description 16
- 239000003112 inhibitor Substances 0.000 claims description 13
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims description 9
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims description 9
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 206010019280 Heart failures Diseases 0.000 claims description 6
- 239000002461 renin inhibitor Substances 0.000 claims description 6
- 229940086526 renin-inhibitors Drugs 0.000 claims description 6
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 4
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims description 4
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- 102000003729 Neprilysin Human genes 0.000 claims 12
- 108090000028 Neprilysin Proteins 0.000 claims 12
- -1 ethyl-aminoacetyl Chemical group 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- ZHUTVLURGLOKMO-UHFFFAOYSA-N 1-acetylpyrrolidine-2-carbonitrile Chemical compound CC(=O)N1CCCC1C#N ZHUTVLURGLOKMO-UHFFFAOYSA-N 0.000 claims 4
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical group C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 claims 4
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 claims 4
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical group COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 claims 4
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 4
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 4
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 4
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims 4
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims 4
- 206010042957 Systolic hypertension Diseases 0.000 claims 4
- 229960004601 aliskiren Drugs 0.000 claims 4
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 4
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 claims 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 4
- 239000000480 calcium channel blocker Substances 0.000 claims 4
- 210000004351 coronary vessel Anatomy 0.000 claims 4
- 239000002934 diuretic Substances 0.000 claims 4
- 230000009977 dual effect Effects 0.000 claims 4
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 4
- 229950011548 fadrozole Drugs 0.000 claims 4
- 208000010125 myocardial infarction Diseases 0.000 claims 4
- 239000002464 receptor antagonist Substances 0.000 claims 4
- 229940044551 receptor antagonist Drugs 0.000 claims 4
- 239000003087 receptor blocking agent Substances 0.000 claims 4
- 208000037803 restenosis Diseases 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 229960004699 valsartan Drugs 0.000 claims 4
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 4
- 230000001882 diuretic effect Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000005541 ACE inhibitor Substances 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical group C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims 2
- 239000002083 C09CA01 - Losartan Substances 0.000 claims 2
- 208000002177 Cataract Diseases 0.000 claims 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 108010061435 Enalapril Proteins 0.000 claims 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 2
- 108010007859 Lisinopril Proteins 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 239000005480 Olmesartan Substances 0.000 claims 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 claims 2
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 claims 2
- 239000002160 alpha blocker Substances 0.000 claims 2
- 229960000528 amlodipine Drugs 0.000 claims 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims 2
- 238000002399 angioplasty Methods 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 229960004530 benazepril Drugs 0.000 claims 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 2
- 239000002876 beta blocker Substances 0.000 claims 2
- 229940097320 beta blocking agent Drugs 0.000 claims 2
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical group COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 claims 2
- 229960003065 bosentan Drugs 0.000 claims 2
- ZTWZVMIYIIVABD-OEMFJLHTSA-N candoxatril Chemical compound C([C@@H](COCCOC)C(=O)OC=1C=C2CCCC2=CC=1)C1(C(=O)N[C@@H]2CC[C@@H](CC2)C(O)=O)CCCC1 ZTWZVMIYIIVABD-OEMFJLHTSA-N 0.000 claims 2
- 229950004548 candoxatril Drugs 0.000 claims 2
- 230000005779 cell damage Effects 0.000 claims 2
- 208000037887 cell injury Diseases 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 208000018631 connective tissue disease Diseases 0.000 claims 2
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 claims 2
- 229960001389 doxazosin Drugs 0.000 claims 2
- 230000001258 dyslipidemic effect Effects 0.000 claims 2
- ODUOJXZPIYUATO-LJQANCHMSA-N ecadotril Chemical compound C([C@H](CSC(=O)C)C(=O)NCC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 ODUOJXZPIYUATO-LJQANCHMSA-N 0.000 claims 2
- 229960000873 enalapril Drugs 0.000 claims 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 2
- 210000002889 endothelial cell Anatomy 0.000 claims 2
- 239000002792 enkephalinase inhibitor Substances 0.000 claims 2
- 229960001208 eplerenone Drugs 0.000 claims 2
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical group C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 206010061989 glomerulosclerosis Diseases 0.000 claims 2
- 229960002003 hydrochlorothiazide Drugs 0.000 claims 2
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- 208000003532 hypothyroidism Diseases 0.000 claims 2
- 230000002989 hypothyroidism Effects 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 229960002394 lisinopril Drugs 0.000 claims 2
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims 2
- 229960004773 losartan Drugs 0.000 claims 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical group CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 229960002237 metoprolol Drugs 0.000 claims 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical group COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims 2
- 229960005117 olmesartan Drugs 0.000 claims 2
- LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical group C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 108700040249 racecadotril Proteins 0.000 claims 2
- 229960003401 ramipril Drugs 0.000 claims 2
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims 2
- 238000007634 remodeling Methods 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 229940030606 diuretics Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000005862 Angiotensin II Human genes 0.000 description 2
- 101800000734 Angiotensin-1 Proteins 0.000 description 2
- 102400000344 Angiotensin-1 Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0212412.1A GB0212412D0 (en) | 2002-05-29 | 2002-05-29 | Combination of organic compounds |
| PCT/EP2003/005639 WO2003099279A1 (en) | 2002-05-29 | 2003-05-28 | Combination of a dpp iv inhibitor and a cardiovascular compound |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010010967A Division JP2010090173A (ja) | 2002-05-29 | 2010-01-21 | Ｄｐｐｉｖ阻害剤および心臓血管化合物の組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005532330A JP2005532330A (ja) | 2005-10-27 |
| JP2005532330A5 true JP2005532330A5 (cg-RX-API-DMAC7.html) | 2006-07-13 |
Family
ID=9937665
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004506803A Withdrawn JP2005532330A (ja) | 2002-05-29 | 2003-05-28 | Ｄｐｐｉｖ阻害剤および心臓血管化合物の組み合わせ |
| JP2010010967A Withdrawn JP2010090173A (ja) | 2002-05-29 | 2010-01-21 | Ｄｐｐｉｖ阻害剤および心臓血管化合物の組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010010967A Withdrawn JP2010090173A (ja) | 2002-05-29 | 2010-01-21 | Ｄｐｐｉｖ阻害剤および心臓血管化合物の組み合わせ |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20060074058A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1511484A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2005532330A (cg-RX-API-DMAC7.html) |
| CN (2) | CN101518650A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003242593A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0311397A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2487167A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO5621286A2 (cg-RX-API-DMAC7.html) |
| GB (1) | GB0212412D0 (cg-RX-API-DMAC7.html) |
| IL (1) | IL165101A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA04011785A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20045557L (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ548971A (cg-RX-API-DMAC7.html) |
| PL (1) | PL372571A1 (cg-RX-API-DMAC7.html) |
| RU (2) | RU2336876C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003099279A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200408990B (cg-RX-API-DMAC7.html) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101273987A (zh) * | 2002-06-03 | 2008-10-01 | 诺瓦提斯公司 | 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途 |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| WO2004087053A2 (en) | 2003-03-25 | 2004-10-14 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| US20040214804A1 (en) * | 2003-04-25 | 2004-10-28 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and an anti-obesity agent |
| EP1625122A1 (en) | 2003-05-14 | 2006-02-15 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US7579357B2 (en) | 2003-08-13 | 2009-08-25 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2005026148A1 (en) | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| RU2385723C2 (ru) * | 2003-11-17 | 2010-04-10 | Новартис Аг | Применение ингибиторов дипептидилпептидазы iv |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| CN102140090A (zh) | 2004-03-15 | 2011-08-03 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
| CA2558020A1 (en) * | 2004-03-17 | 2005-09-29 | Novartis Ag | Use of renin inhibitors in therapy |
| WO2005099695A1 (en) * | 2004-04-19 | 2005-10-27 | Novartis Ag | Drug delivery systems for the prevention and treatment of vascular diseases |
| EP1753730A1 (en) | 2004-06-04 | 2007-02-21 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| RU2384346C2 (ru) * | 2004-06-23 | 2010-03-20 | Зольвай Фармасьютиклз Гмбх | Фармацевтические композиции, содержащие nep-ингибиторы, ингибиторы эндогенной эндотелинпродуцирующей системы и антагонисты at1-рецептора |
| WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| RU2407523C2 (ru) * | 2004-10-08 | 2010-12-27 | Новартис Аг | Применение ингибиторов ренина для профилактики или лечения диастолической дисфункции или диастолической сердечной недостаточности |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| JP2008524331A (ja) | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
| SI1830869T1 (sl) | 2004-12-24 | 2013-12-31 | Spinifex Pharmaceuticals Pty Ltd | Postopek zdravljenja ali profilakse |
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| MY146830A (en) * | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
| GB0503062D0 (en) * | 2005-02-14 | 2005-03-23 | Novartis Ag | Combination of organic compounds |
| JP4568361B2 (ja) | 2005-04-22 | 2010-10-27 | アラントス・ファーマシューティカルズ・ホールディング・インコーポレーテッド | ジペプチジルペプチダーゼ−ｉｖ阻害剤 |
| WO2006137222A1 (ja) * | 2005-06-24 | 2006-12-28 | Tokyo Medical And Dental University | 薬剤溶出速度制御方法、及び薬剤溶出性ステント被膜用組成物 |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| US20130131007A1 (en) | 2005-09-07 | 2013-05-23 | Bebaas, Inc. | Vitamin b12 compositions |
| EP1942898B2 (en) | 2005-09-14 | 2014-05-14 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
| CN101360723A (zh) | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | 制备嘧啶二酮衍生物的方法 |
| US20070196510A1 (en) * | 2006-02-17 | 2007-08-23 | Gerber Michael J | Method for treating resistant hypertension |
| CN101443001B (zh) | 2006-03-20 | 2013-11-13 | 西芬克斯医药有限公司 | 治疗或预防炎性痛的方法 |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| NZ600394A (en) | 2006-05-04 | 2014-04-30 | Boehringer Ingelheim Int | Polymorphs of a dpp-iv enzyme inhibitor |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| CA2677214A1 (en) * | 2007-02-01 | 2008-08-07 | Nephrogen, Llc | Potentiation of stem cell homing and treatment of organ dysfunction or organ failure |
| US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| CA2697057A1 (en) | 2007-08-22 | 2009-02-26 | Gilead Colorado, Inc. | Therapy for complications of diabetes |
| EP2062874B1 (en) | 2007-11-20 | 2014-12-17 | KRKA, tovarna zdravil, d.d., Novo mesto | Process and intermediates for the preparation of aliskiren |
| AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
| EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| UA102502C2 (uk) * | 2008-08-08 | 2013-07-25 | Віктор Павлович Кутняк | Антигіпертензивна органічна сіль |
| MX2011002558A (es) | 2008-09-10 | 2011-04-26 | Boehringer Ingelheim Int | Terapia de combinacion para el tratamiento de diabetes y estados relacionados. |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| SI2189442T1 (sl) | 2008-11-20 | 2015-03-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Postopek in intermediati za pripravo aliskirena |
| CA2745037C (en) | 2008-12-23 | 2020-06-23 | Boehringer Ingelheim International Gmbh | Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8(3-(r)-amino-piperidin-1-yl)-xanthine |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| CN102753161A (zh) | 2009-11-27 | 2012-10-24 | 贝林格尔.英格海姆国际有限公司 | 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗 |
| NZ601077A (en) * | 2010-01-14 | 2014-07-25 | Novartis Ag | Use of an adrenal hormone-modifying agent |
| JP2013523819A (ja) | 2010-04-06 | 2013-06-17 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置 |
| CN107961377B (zh) | 2010-05-05 | 2022-11-22 | 勃林格殷格翰国际有限公司 | 组合疗法 |
| MX2012014247A (es) | 2010-06-24 | 2013-01-18 | Boehringer Ingelheim Int | Terapia para la diabetes. |
| EP3323818A1 (en) | 2010-09-22 | 2018-05-23 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| AR083878A1 (es) * | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| PT2640371T (pt) * | 2010-11-15 | 2020-04-17 | Boehringer Ingelheim Int | Terapia antidiabética vasoprotetora e cardioprotetora |
| WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| CN102247345A (zh) * | 2011-05-30 | 2011-11-23 | 北京阜康仁生物制药科技有限公司 | 一种新型降血脂组合物 |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| PL2731947T3 (pl) | 2011-07-15 | 2019-07-31 | Boehringer Ingelheim International Gmbh | Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II |
| CA2846387C (en) * | 2011-08-26 | 2016-02-09 | Wockhardt Limited | Methods for treating cardiovascular disorders |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| US20130303554A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in sirs and/or sepsis |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| PT3015106T (pt) | 2013-06-26 | 2021-09-06 | Univ Korea Res & Bus Found | Composição para prevenção ou tratamento de doenças renais, compreendendo um inibidor da dpp-iv |
| WO2015128453A1 (en) | 2014-02-28 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Medical use of a dpp-4 inhibitor |
| HK1249847A1 (zh) | 2015-03-09 | 2018-11-16 | Intekrin Therapeutics, Inc. | 用於治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法 |
| CA3022202A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
| BR112019020485A2 (pt) | 2017-04-03 | 2020-05-12 | Coherus Biosciences, Inc. | Agonista ppary para tratamento de paralisia supranuclear progressiva |
| CN107029208A (zh) * | 2017-06-13 | 2017-08-11 | 江苏黄河药业股份有限公司 | 一种治疗心血管疾病的赖诺普利复方制剂及其制备方法 |
| EA034975B1 (ru) * | 2018-03-13 | 2020-04-13 | Владимир Александрович Горшков-Кантакузен | Способ лечения лабильной и пароксизмальной гипертензии |
| CN116688135B (zh) * | 2023-07-28 | 2024-10-29 | 四川大学华西医院 | 一种骨关节炎药物治疗组合物及其制备方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5175187A (en) * | 1989-03-06 | 1992-12-29 | Soorianarain Baligadoo | Synergistic compositions for the treatment of coronary insufficiency and methods of use thereof |
| US5350771A (en) * | 1989-03-22 | 1994-09-27 | Peter K. T. Pang | Method and treatment for hypertension using combination therapy involving exogenous calcium and calcium channel blockers |
| AU4794393A (en) * | 1992-07-31 | 1994-03-03 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Producing increased numbers of hematopoietic cells by administering inhibitors of dipeptidyl peptidase iv |
| US5780473A (en) * | 1995-02-06 | 1998-07-14 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
| BR9609066A (pt) * | 1995-06-07 | 1999-01-26 | Searle & Co | Antagonista aldoesterone epoxi-esteroidal e terapia de combinação de antagonista angiotensina ii para tratamento de deficiência do coração |
| US5645839A (en) * | 1995-06-07 | 1997-07-08 | Trustees Of Boston University | Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis |
| US6008221A (en) * | 1996-11-06 | 1999-12-28 | Bristol-Myers Squibb Company | Method for treating Alzheimer's disease with folic acid |
| ATE225187T1 (de) * | 1997-12-23 | 2002-10-15 | Warner Lambert Co | Ace hemmer/matrix metalloproteinase hemmer- arzneimittelkombinationen |
| US6204281B1 (en) * | 1998-07-10 | 2001-03-20 | Novartis Ag | Method of treatment and pharmaceutical composition |
| AU5480199A (en) * | 1998-08-21 | 2000-03-14 | Point Therapeutics, Inc. | Regulation of substrate activity |
| WO2001052825A2 (en) * | 2000-01-21 | 2001-07-26 | Novartis Ag | Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
| GB0014969D0 (en) * | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
| US20020037829A1 (en) * | 2000-08-23 | 2002-03-28 | Aronson Peter S. | Use of DPPIV inhibitors as diuretic and anti-hypertensive agents |
-
2002
- 2002-05-29 GB GBGB0212412.1A patent/GB0212412D0/en not_active Ceased
-
2003
- 2003-05-28 US US10/515,864 patent/US20060074058A1/en not_active Abandoned
- 2003-05-28 CN CNA2009100075473A patent/CN101518650A/zh active Pending
- 2003-05-28 PL PL03372571A patent/PL372571A1/xx not_active Application Discontinuation
- 2003-05-28 WO PCT/EP2003/005639 patent/WO2003099279A1/en not_active Ceased
- 2003-05-28 RU RU2004139025/15A patent/RU2336876C2/ru not_active IP Right Cessation
- 2003-05-28 EP EP03755149A patent/EP1511484A1/en not_active Withdrawn
- 2003-05-28 AU AU2003242593A patent/AU2003242593A1/en not_active Abandoned
- 2003-05-28 CA CA002487167A patent/CA2487167A1/en not_active Abandoned
- 2003-05-28 BR BR0311397-3A patent/BR0311397A/pt not_active IP Right Cessation
- 2003-05-28 MX MXPA04011785A patent/MXPA04011785A/es active IP Right Grant
- 2003-05-28 CN CNA038121840A patent/CN1655786A/zh active Pending
- 2003-05-28 NZ NZ548971A patent/NZ548971A/en not_active IP Right Cessation
- 2003-05-28 NZ NZ536758A patent/NZ536758A/en not_active IP Right Cessation
- 2003-05-28 JP JP2004506803A patent/JP2005532330A/ja not_active Withdrawn
-
2004
- 2004-11-05 ZA ZA200408990A patent/ZA200408990B/en unknown
- 2004-11-08 IL IL16510104A patent/IL165101A0/xx unknown
- 2004-12-13 CO CO04124517A patent/CO5621286A2/es not_active Application Discontinuation
- 2004-12-20 NO NO20045557A patent/NO20045557L/no not_active Application Discontinuation
-
2007
- 2007-08-03 US US11/815,536 patent/US20070293474A1/en not_active Abandoned
-
2008
- 2008-05-21 RU RU2008119956/15A patent/RU2008119956A/ru not_active Application Discontinuation
-
2010
- 2010-01-21 JP JP2010010967A patent/JP2010090173A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005532330A5 (cg-RX-API-DMAC7.html) | ||
| RU2336876C2 (ru) | Комбинация ингибитора дипептидилпептидазы iv (dpp iv) и сердечно-сосудистого вещества | |
| JP6373931B2 (ja) | 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤 | |
| KR20120126133A (ko) | 디펩티딜 펩티다제 ⅳ 억제제의 용도 | |
| CN107405406A (zh) | 用于治疗肺纤维化的血管紧张素ii受体激动剂 | |
| KR20100137026A (ko) | 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는 약제학적 조성물 | |
| AU2004204352B2 (en) | Pharmaceutical combination of telmisartan and atorvastatin for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases | |
| CA2214143A1 (en) | Combination compositions containing benazepril or benazeprilat and valsartan | |
| Hosoya et al. | Protection of the cardiovascular system by imidapril, a versatile angiotensin‐converting enzyme inhibitor | |
| Makówka et al. | A comparison of the antihypertensive and anti-inflammatory effects of aliskiren and ramipril add-on therapy in peritoneal dialysis patients–a pilot open label study | |
| Morganti et al. | Aliskiren: the first direct renin inhibitor available for clinical use | |
| AU766453C (en) | Use of angiotensin II receptor antagonists for treating acute myocardial infarction | |
| JP2006515877A (ja) | 心臓血管、心肺、肺又は腎疾患の予防又は治療のための医薬併用剤 | |
| WO2006041763A1 (en) | Renin inhibitors for treating transplantation induced diseases | |
| KR20050016452A (ko) | Ｄｐｐ ⅳ 억제제와 심혈관계 화합물의 조합물 | |
| Waeber et al. | Clinical Applications and Limitations in the Use of AT1 Receptor Antagonists |